'Authorized Biosimilars' Can't Use 351(k) Pathway, US FDA Concludes

 
• By Sue Sutter
Calendar_23_March
US FDA is finalizing preparations for the regulatory transition that will take place on 23 March. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics